Esperion to Participate in Upcoming September Investor Conferences

Rhea-AI Summary

Esperion (NASDAQ: ESPR), a commercial stage biopharmaceutical company, announced its participation in two upcoming investor conferences in September 2025: the Cantor Global Healthcare Conference on September 3 at 9:45 a.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 2:00 p.m. ET.

The company specializes in FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk, supported by the 14,000-patient CLEAR Cardiovascular Outcomes Trial. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through partnerships and pipeline advancement.

News Market Reaction – ESPR

+1.86%

+1.86% Session close to close

In the Aug 26 session, ESPR gained 1.86%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of September, which can be found on our investor relations website.

Cantor Global Healthcare Conference in New York on September 3, 2025, at 9:45 a.m. ET.

H.C. Wainwright 27^th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 p.m. ET.

Live webcasts can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information: 
Investors:  
Alina Venezia 
investorrelations@esperion.com
(734) 887-3903 

Media:  
Tiffany Aldrich  
corporateteam@esperion.com
(616) 443-8438 

FAQ

When is Esperion (ESPR) presenting at the Cantor Global Healthcare Conference 2025?

Esperion will present at the Cantor Global Healthcare Conference in New York on September 3, 2025, at 9:45 a.m. ET.

What time is Esperion's presentation at the H.C. Wainwright Conference in September 2025?

Esperion will present at the H.C. Wainwright Global Investment Conference on September 8, 2025, at 2:00 p.m. ET in New York.

How can investors access Esperion's September 2025 conference presentations?

Investors can access the live webcasts through the investor and media section of Esperion's website. Webcast replays will be available approximately two hours after each presentation and archived for about 90 days.

What are Esperion's main products and focus areas in 2025?

Esperion focuses on FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk, supported by their 14,000-patient CLEAR trial. They're also developing next-generation ATP citrate lyase inhibitors (ACLYi).